{"name":"Vanderbilt-Ingram Cancer Center","slug":"vanderbilt-ingram-cancer-center","ticker":"","exchange":"","domain":"vicc.org","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-08-27","label":"ticilimumab Phase 3 readout (Hepatocellular Carcinoma)","drug":"ticilimumab","drugSlug":"ticilimumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"ticilimumab Phase 3 readout (Non-Small-Cell Lung Carcinoma NSCLC)","drug":"ticilimumab","drugSlug":"ticilimumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-12-31","label":"ticilimumab Phase 3 readout (Non Small Cell Lung Carcinoma NSCLC)","drug":"ticilimumab","drugSlug":"ticilimumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-02-26","label":"ticilimumab Phase 3 readout (Hepatocellular Carcinoma)","drug":"ticilimumab","drugSlug":"ticilimumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-07-01","label":"ticilimumab Phase 3 readout (OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC))","drug":"ticilimumab","drugSlug":"ticilimumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-10-10","label":"ticilimumab Phase 3 readout (Hepatocellular Carcinoma (HCC))","drug":"ticilimumab","drugSlug":"ticilimumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-09-01","label":"ticilimumab Phase 2 readout (Hepatocellular Carcinoma)","drug":"ticilimumab","drugSlug":"ticilimumab","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"Hormonal Therapy","genericName":"Hormonal Therapy","slug":"hormonal-therapy","indication":"Other","status":"phase_2"},{"name":"Bisphosphonates","genericName":"Bisphosphonates","slug":"bisphosphonates","indication":"Other","status":"marketed"},{"name":"Erlotinb","genericName":"Erlotinb","slug":"erlotinb","indication":"Other","status":"phase_2"},{"name":"Nivo800","genericName":"Nivo800","slug":"nivo800","indication":"Other","status":"phase_1"},{"name":"PI3K inhibitor BYL719","genericName":"PI3K inhibitor BYL719","slug":"pi3k-inhibitor-byl719","indication":"Other","status":"phase_1"},{"name":"TGR-1202","genericName":"TGR-1202","slug":"tgr-1202","indication":"Relapsed or refractory B-cell malignancies","status":"phase_3"},{"name":"cyclosporine ophthalmic emulsion","genericName":"cyclosporine ophthalmic emulsion","slug":"cyclosporine-ophthalmic-emulsion","indication":"Prevention of corneal transplant rejection","status":"phase_3"},{"name":"ticilimumab","genericName":"ticilimumab","slug":"ticilimumab","indication":"Other","status":"discontinued"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Cetuximab (EGFR inhibitor)","genericName":"Cetuximab (EGFR inhibitor)","slug":"cetuximab-egfr-inhibitor","indication":"Metastatic colorectal cancer (KRAS wild-type)","status":"marketed"},{"name":"Copper Cu 64 Dotatate","genericName":"Copper Cu 64 Dotatate","slug":"copper-cu-64-dotatate","indication":"PET imaging of somatostatin receptor-positive neuroendocrine tumors","status":"marketed"},{"name":"Magic Mouthwash","genericName":"Magic Mouthwash","slug":"magic-mouthwash","indication":"Chemotherapy-induced oral mucositis","status":"phase_3"}]}],"pipeline":[{"name":"Hormonal Therapy","genericName":"Hormonal Therapy","slug":"hormonal-therapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bisphosphonates","genericName":"Bisphosphonates","slug":"bisphosphonates","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cetuximab (EGFR inhibitor)","genericName":"Cetuximab (EGFR inhibitor)","slug":"cetuximab-egfr-inhibitor","phase":"marketed","mechanism":"Cetuximab is a monoclonal antibody that binds to and blocks the epidermal growth factor receptor (EGFR), preventing ligand-induced activation and downstream proliferation signaling in cancer cells.","indications":["Metastatic colorectal cancer (KRAS wild-type)","Squamous cell carcinoma of the head and neck","Non-small cell lung cancer (EGFR-expressing)"],"catalyst":""},{"name":"Copper Cu 64 Dotatate","genericName":"Copper Cu 64 Dotatate","slug":"copper-cu-64-dotatate","phase":"marketed","mechanism":"Copper Cu 64 Dotatate is a radioactive imaging agent that binds to somatostatin receptors on neuroendocrine tumor cells, allowing PET visualization and localization of these tumors.","indications":["PET imaging of somatostatin receptor-positive neuroendocrine tumors"],"catalyst":""},{"name":"Erlotinb","genericName":"Erlotinb","slug":"erlotinb","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Magic Mouthwash","genericName":"Magic Mouthwash","slug":"magic-mouthwash","phase":"phase_3","mechanism":"Magic Mouthwash is a topical oral rinse that combines local anesthetics, antimicrobials, and anti-inflammatory agents to relieve oral mucositis pain and promote healing in cancer patients.","indications":["Chemotherapy-induced oral mucositis","Radiation-induced oral mucositis","Cancer treatment-related oral pain and inflammation"],"catalyst":""},{"name":"Nivo800","genericName":"Nivo800","slug":"nivo800","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PI3K inhibitor BYL719","genericName":"PI3K inhibitor BYL719","slug":"pi3k-inhibitor-byl719","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TGR-1202","genericName":"TGR-1202","slug":"tgr-1202","phase":"phase_3","mechanism":"TGR-1202 is a selective inhibitor of the PI3K delta subunit.","indications":["Relapsed or refractory B-cell malignancies"],"catalyst":""},{"name":"cyclosporine ophthalmic emulsion","genericName":"cyclosporine ophthalmic emulsion","slug":"cyclosporine-ophthalmic-emulsion","phase":"phase_3","mechanism":"Cyclosporine ophthalmic emulsion works by suppressing the immune system to prevent rejection of transplanted corneal tissue.","indications":["Prevention of corneal transplant rejection"],"catalyst":""},{"name":"ticilimumab","genericName":"ticilimumab","slug":"ticilimumab","phase":"discontinued","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQZml6RzVhLTEzbGJETFdHN0tJeVBsalY0MmFtcTJmY1BUblVKdFZFZUVlT1VleWh0RWN5WFUtWjloTDhQNXVKRkpmODMxTG9DRVlUaGZobG85VEQ0Z1Q5NWkyYmlpT3dHbDRSLXU5ZmsxNjFnMGQzNWUyV0VsWU1pTTRhRS16MTRfU2F3S2U3aDFNY0dKdnE5VngwZDVqVUN5eGdtMVpKdHVBRkFiUTI0Um0yejZOSEpKbm5YRVRsbzAtSXgtY2FwNFkzLWNnbEdHdmduWDNZenpZeTE0T0ZoSXNEdVp4LWw4YVMzOG4yUlV1cTBDSVNfRWx4Qm5FQQ?oc=5","date":"2025-12-02","type":"pipeline","source":"Business Wire","summary":"SUO and Ferring Pharmaceuticals Announce the SUO Non-Muscle Invasive Bladder Cancer (NMIBC) Fellows Research Grant - Business Wire","headline":"SUO and Ferring Pharmaceuticals Announce the SUO Non-Muscle Invasive Bladder Cancer (NMIBC) Fellows Research Grant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE1Bb0FyQjZKdERTcENKc3ctWmpTVE51NGN5UXI5Z1dnNmN0WmxFWndJdW01Mzh6ZXJBY2RBN2p0dV92em15NUxydHRKdkVrSk1GS29qQXRRMA?oc=5","date":"2025-09-23","type":"pipeline","source":"VUMC News","summary":"Cell Power - VUMC News","headline":"Cell Power","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQMGxRcGRWMV9ZVWFka2xmQUt5MVFKaVZsTjJxUWIzVWlFSnNwSk1XX0tFaWVtdmdHYkY4VW43cUdNN2tmVzJUTjZkWUtKb2IycXZacHVFOVU2dFhvNkdwVTR5Y1ZhenV2bVFqYVMyTk10NHZTZl8yN0Rtb29YZjdtVmowblNyakhpVEJjZ1VOX1pDSFJCUU14RjkxT1JuWTJQVEVBa1VkT0hjLVBJa2F6RVR2MEZnUHJ2TUUxT0R3NlNvbWhRLXN2NnlfbGhwYnB2bWphaUhneEx0WEtjUkljeWpYMldRYlFKUWJibFpVeFJXZ2xDOExN?oc=5","date":"2025-09-11","type":"pipeline","source":"PR Newswire","summary":"Vanderbilt-Ingram Cancer Center Featured on \"Empowered with Meg Ryan\" in a Segment Focused on Hope and Healing - PR Newswire","headline":"Vanderbilt-Ingram Cancer Center Featured on \"Empowered with Meg Ryan\" in a Segment Focused on Hope and Healing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQSWh2cjBjM1loVlEwYW1BR2ZnUXNURjd5NlUtdXNvZXRCOEg1aEtPMktEZjFEZGFIMGptbWdFWHBpYmNZM0txeGN0SHotU0F1UnQ3M0xyZGFzQTcxN3BrRGhRQzlwVDBRMnN0TDBOMWNxd1JNLW56d0cxbks1b0F6Wk0zOVZsb0g3WEMycEFVaUdNbGNlazBjWERpcGU?oc=5","date":"2025-05-21","type":"regulatory","source":"Targeted Oncology","summary":"FDA ODAC Votes 5 to 4 Against UGN-102 for Recurrent LG-IR-NMIBC - Targeted Oncology","headline":"FDA ODAC Votes 5 to 4 Against UGN-102 for Recurrent LG-IR-NMIBC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNWFZ2aXoxNHo2RGZRWkZJX0VEaGpkYUxYak5zUjVUTWUxQUNOazJscklkVjM2a2VEWTdESEJabGRMSVY4Nk44WFlqM0xlX2V2N2N3c2ZWbkIzMmtNbFN1Y2p1eWFkc2ZIellNQWRSVVFpdnR2RE5Pb0owbGhQWjdweEJfaWQ?oc=5","date":"2025-03-24","type":"pipeline","source":"The American Journal of Managed Care® (AJMC®)","summary":"Elevating Cancer Care Through Personalized Treatment - The American Journal of Managed Care® (AJMC®)","headline":"Elevating Cancer Care Through Personalized Treatment - The American Journal of Managed Care® (AJMC®)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOMmdodldVTmROekJxLURYMjR4NGtvbkp3enhJaVR4bDI1ZGNPSTU3UWo3X3pmaUpLcU1KR1FaNUZQZmYwTFF6UWxGSlZRb3NYRFpuREVSZ3BZc1dsWVFGSXQweVQ1dW1fcnhYUHRhQ2gxOGNBYlJocnQzUFl0QjdkMnhUMldfZ1NZa2txZmRuOFEwYTFYU20xUm03cw?oc=5","date":"2025-01-13","type":"pipeline","source":"VUMC News","summary":"Vanderbilt-Ingram Cancer Center Lebanon moves to new location - VUMC News","headline":"Vanderbilt-Ingram Cancer Center Lebanon moves to new location","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQNjN2dENyZS1zRk1DOFFzTTdSUFRlcXZnLXpWLUN5UHFTT1pWM3NUUWpnR0h0UUdMcW5MUjNfNU0yZDJKZlJ2UjJ4NXJkNWRaSGQ4ZW9KSnJLZ0J4S0hVUVYySzQ5dlFLYXA3MGRZbzNaUFQyQmZBc3EtOGQ2UGVVR2owZmg2czlxZmZfUEFYQ0ZGT2lBOUVkVlp0Q0gwTktJUDhjRlY5ZzNkdGpQeHotbFNVMDZCYm05WUdzQ0pNZGpJYkRDVnJXd1h6LV9YdVNlYy1WeXVNR3dLT253TmpOOUJGTQ?oc=5","date":"2024-10-15","type":"deal","source":"VUMC News","summary":"Cathy Eng named Vanderbilt-Ingram Cancer Center associate director of Strategic Relations and Research Partnerships - VUMC News","headline":"Cathy Eng named Vanderbilt-Ingram Cancer Center associate director of Strategic Relations and Research Partnerships","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOMXVZc1Z0MG1jQVhYS2JmOXlRbGhtTEs1Q1MtczhxTEFVSWVaYldIYkdlZGRHNWk3YVByTFFJUG8yb2pkOWxDRXR3UVNBdVRUbk9Ec0xOaVNjOW5iVDZ5RjZQSDRYbE1nV09xclZITG40ajcwVDRyV050N3R3VlFobEtnVQ?oc=5","date":"2024-07-30","type":"pipeline","source":"VUMC News","summary":"Ingrams add to cancer-fight war chest - VUMC News","headline":"Ingrams add to cancer-fight war chest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQUnZ4OGdGbVhndGo0SEtpWWxjazdEdnV3OFVNbDdrRkFUcklReUw2T20yT2xwNFlhUUZmZDlCUVRjRFJSODFPdGRLaDJNa1RJNVdkNTZBT2tTVXJ0SXgyck5HN0RsNTBhaGxlOG5LSFBEd1ZRZkdxRTZVZ0ZFNjBVWXJ2TngtNzdpYzZLMTFRQXk1Qlp1VHh5QzJhcw?oc=5","date":"2023-12-20","type":"pipeline","source":"VUMC News","summary":"Appointments, additions in 2023 strengthen VUMC’s core missions - VUMC News","headline":"Appointments, additions in 2023 strengthen VUMC’s core missions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPX1ZYd0w2dTJ4VnVFc0MwRkUwQWxnQ19hWEVwZ2l5bFZIMjNxV2xLSDAyYTdLYXotZDJER3JOVEJLSzMtRzZYaVJiLWwwX0VDalNHMFdON2pVdE4yQUxOVF9HN0xZNDlpVGNLWWIwOVRUaC1ON3NsNmpHbTRMWVVZMVdoM2xMQmdSdk1vamFodTJtQnVkS3lyLTln?oc=5","date":"2023-03-16","type":"trial","source":"VUMC News","summary":"Eng stresses need for clinical trial support at cancer forum - VUMC News","headline":"Eng stresses need for clinical trial support at cancer forum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNbDl1a0hZMi16WUZ0S3VHdGhLeVA0ejF3WGdiT1ZwRjdZblMyRVFJYmJnZW14SDNyTjR2M0NhalNDMm9ycXl3M0loVlJkN0tlLU9QMVN0enFtSjh1cU1TSmt6bzg2TlNERVlhVURXZ0tlZEZRemtfYnFSUl9tZTVDTGwzQmM4X19NaF9EZkM2cDhkQkI0VXBQZGlyd05XVmI3enAyLURPUEt1Zw?oc=5","date":"2023-02-09","type":"pipeline","source":"VUMC News","summary":"Mark Cuban pharmacy could save billions on prostate cancer, bladder drugs - VUMC News","headline":"Mark Cuban pharmacy could save billions on prostate cancer, bladder drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxOUnE1UFhiVi1rcW0wdTM0dzJ4RFFHdTUzbm9ibW4zc3k2TGtiaFI0SXFVeXQwaUp2TVl4OXZCQlpEbUNxcEdQSHpqTXY1R0RzdG9EVkRqZWkxT0MyNWJZUFhPWHRoRUtwTWd4X28tQnBXMFpqMTJDbkExRXIyNkJXRC1tdmNKbV9yeVMzb0NVemZmc3lsNjNzTllhRGswOFQ0Q2V4T2xFanBzYUs0MUw5UHYyYXFnSEUtUF9QWjFodU52T3NEblk3MmktVTRUSlZUejc4Q3VFN0JEc3BwOHFZaXV4Z1llem9VYjhXUUJTYVRkWWUtc3ExblFJUHd0ZmNZTDBkMw?oc=5","date":"2021-09-29","type":"deal","source":"Nashville Post","summary":"NIH renews funding for Meharry, Vanderbilt, TSU cancer research partnership - Nashville Post","headline":"NIH renews funding for Meharry, Vanderbilt, TSU cancer research partnership","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_2":2,"marketed":3,"phase_3":3,"phase_1":2,"discontinued":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}